Literature DB >> 9856816

Expression of interleukin-12 is increased in psoriatic skin.

N Yawalkar1, S Karlen, R Hunger, C U Brand, L R Braathen.   

Abstract

Although the precise underlying pathomechanisms of psoriasis have not been fully elucidated, previous reports suggest that T helper 1-type cytokines are critically involved in the pathogenesis of this disease. Interleukin-12 (IL-12), a heterodimeric cytokine, has been suggested to play a major role in the development of T helper 1 cell responses. In this study, the presence of IL-12 mRNA and protein was investigated in normal human skin as well as nonlesional and lesional psoriatic skin. Messenger RNA levels were determined in biopsy specimens by a standard and a nested reverse transcriptase-polymerase chain reaction method. Additionally, IL-12 protein expression was analyzed in situ by immunohistochemistry using an antibody recognizing IL-12 p70. Whereas specific transcripts for IL-12 p35 were reproducibly detected without any significant differences in all samples, enhanced IL-12 p40 mRNA signals were only found in lesional psoriatic skin as compared with normal and nonlesional psoriatic skin. Furthermore, immunoreactivity for IL-12 p70 was markedly increased in the psoriatic skin lesions and was predominantly expressed on mononuclear cells in the dermis. In conclusion, our data suggest a critical role for IL-12 in promoting and maintaining T cell activation and inducing T helper 1-type cytokines such as interferon-gamma in psoriasis. We speculate that IL-12 might be a key cytokine in the pathogenesis of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856816     DOI: 10.1046/j.1523-1747.1998.00446.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  53 in total

Review 1.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.

Authors:  Kiyoshi Hirahara; Toshinori Nakayama
Journal:  Int Immunol       Date:  2016-02-12       Impact factor: 4.823

3.  Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.

Authors:  Chuanpu Hu; Bruce Randazzo; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-20       Impact factor: 2.745

Review 4.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

Review 5.  Psoriatic arthritis: current topics.

Authors:  David McCarey; Iain B McInnes
Journal:  Curr Rheumatol Rep       Date:  2007-12       Impact factor: 4.592

6.  Ustekinumab.

Authors:  Kristian Reich; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

7.  Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis.

Authors:  Chuanpu Hu; Yasmine Wasfi; Yanli Zhuang; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-05-23       Impact factor: 2.745

Review 8.  The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.

Authors:  Caitriona Ryan; Alan Menter; Richard B Warren
Journal:  Mol Diagn Ther       Date:  2010-04-01       Impact factor: 4.074

9.  A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

Authors:  Chuanpu Hu; Zhenling Yao; Yang Chen; Bruce Randazzo; Liping Zhang; Zhenhua Xu; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-16       Impact factor: 2.745

Review 10.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.